Search

Filter Options

Active Development

Reset

Delivery Type

Reset

Duration Type

Reset

Developer

Reset

User

Reset

Hormonal

Reset

Development Stage

Reset

Potential MPT

Reset

API

Reset
View by user and type (hormonal or non-hormonal)
Displaying 1 - 10 of 243
Alternative Name: 11b-methyl-19-nortestosterone 17b-dodecylcarbonate (11b-MNTDC)
User: Male
Hormonal: Yes
Delivery Method: Injectable, Oral
Developer: BIOQUAL, Inc.
Development Stage: Lead Optimization
Development Phase: Discovery and Early Development
User: Female
Hormonal: No
Duration Type: Long-acting
Delivery Method: Intrauterine
Developer: Shandong Provincial Institute, China, Technology for Family Planning, China
Development Stage: Pre-clinical
Development Phase: Pre-Clinical and Clinical Development
Alternative Name: Smaller/Nulliparous Copper IUD, Liberté TT380 Short, Micro T
User: Female
Hormonal: No
Duration Type: Long-acting
Delivery Method: Intrauterine
Developer: 7Med Industrie, France
Development Stage: SRA/WHO PQ Approved
Development Phase: Limited Market Availability
Alternative Name: Abhydrolase Domain Containing 2, 2-Arachidonoylglycerol Hydrolase, Monoacylglycerol Lipase ABHD2, Lung Alpha/Beta Hydrolase 2, Protein PHPS1-2, LABH2, Alpha/Beta Hydrolase Domain Containing Protein 2
Target
Hormonal: No
Development Stage: Target Validation
Development Phase: Discovery and Early Development
Alternative Name: Acrosomal Vesicle Protein 1, Acrosomal Protein SP-10, Sperm Protein 10, D11S4365, SPACA2, SP-10
Target
User: Female
Hormonal: No
Development Stage: Target Validation
Development Phase: Discovery and Early Development
Alternative Name: GnRH II Receptor Antagonists
Hormonal: Yes
Developer: CICRR, San Antonio, CONRAD
Development Stage: Compound ID/Selection
Development Phase: Discovery and Early Development
Alternative Name: ADAM Metallopeptidase Domain 2, Fertilin β, Cancer/Testis Antigen 15, Disintegrin And Metalloproteinase Domain-Containing Protein 2, PH30-Beta, FTNB, CT15, PH30, EC 3.4.24, PH-30b, CRYN1, CRYN2, PH-30
Target
User: Female, Male
Hormonal: No
Development Stage: Target Validation
Development Phase: Discovery and Early Development
Alternative Name: Adenylate Cyclase 10 and cyclic adenosine monophopshate, sAC and cAMP, soluble adenylyl cyclase
Target
User: Female, Male
Hormonal: No
Development Stage: Target Validation
Development Phase: Discovery and Early Development
Alternative Name: Androglobin, Calpain-7-Like Protein, C6orf103, Chromosome 6 Open Reading Frame 103, CAPN16, CAPN7L
Target
User: Female, Male
Hormonal: No
Development Stage: Target Identification
Development Phase: Discovery and Early Development
Alternative Name: AF-2364
User: Female, Male
Hormonal: No
Duration Type: Short-acting
Delivery Method: Injectable, Oral, Other
Developer: Population Council
Development Stage: Lead Optimization
Development Phase: Discovery and Early Development

Pages

Displaying 1 - 10 of 70
Alternative Name: 11b-methyl-19-nortestosterone 17b-dodecylcarbonate (11b-MNTDC)
User: Male
Hormonal: Yes
Delivery Method: Injectable, Oral
Developer: BIOQUAL, Inc.
Development Stage: Lead Optimization
Alternative Name: Abhydrolase Domain Containing 2, 2-Arachidonoylglycerol Hydrolase, Monoacylglycerol Lipase ABHD2, Lung Alpha/Beta Hydrolase 2, Protein PHPS1-2, LABH2, Alpha/Beta Hydrolase Domain Containing Protein 2
Target
Hormonal: No
Development Stage: Target Validation
Alternative Name: Acrosomal Vesicle Protein 1, Acrosomal Protein SP-10, Sperm Protein 10, D11S4365, SPACA2, SP-10
Target
User: Female
Hormonal: No
Development Stage: Target Validation
Alternative Name: GnRH II Receptor Antagonists
Hormonal: Yes
Developer: CICRR, San Antonio, CONRAD
Development Stage: Compound ID/Selection
Alternative Name: ADAM Metallopeptidase Domain 2, Fertilin β, Cancer/Testis Antigen 15, Disintegrin And Metalloproteinase Domain-Containing Protein 2, PH30-Beta, FTNB, CT15, PH30, EC 3.4.24, PH-30b, CRYN1, CRYN2, PH-30
Target
User: Female, Male
Hormonal: No
Development Stage: Target Validation
Alternative Name: Adenylate Cyclase 10 and cyclic adenosine monophopshate, sAC and cAMP, soluble adenylyl cyclase
Target
User: Female, Male
Hormonal: No
Development Stage: Target Validation
Alternative Name: Androglobin, Calpain-7-Like Protein, C6orf103, Chromosome 6 Open Reading Frame 103, CAPN16, CAPN7L
Target
User: Female, Male
Hormonal: No
Development Stage: Target Identification
Alternative Name: AF-2364
User: Female, Male
Hormonal: No
Duration Type: Short-acting
Delivery Method: Injectable, Oral, Other
Developer: Population Council
Development Stage: Lead Optimization
Alternative Name: Mullerian-inhibiting Substance (MIS), Mullerian-inhibiting Hormone (MIH), Mullerian-inhibiting Factor (MIF), Mullerian Duct Inhibitory Factor (MDIF), Mullerian Regression Factor (MRF), Anti-paramesonephric Hormone (APH)
Development Stage: Lead Optimization
Alternative Name: Astacin Like Metalloendopeptidase, Ovastacin, Sperm Acrosomal SLLP1 Binding, SAS1B, Oocyte Astacin, EC 3.4
Target
User: Female
Hormonal: No
Development Stage: Target Validation

Pages

Displaying 1 - 10 of 121
User: Female
Hormonal: No
Duration Type: Long-acting
Delivery Method: Intrauterine
Developer: Shandong Provincial Institute, China, Technology for Family Planning, China
Development Stage: Pre-clinical
Alternative Name: Inhibitors of Testicular Retinoic Acid Biosynthesis
User: Male
Hormonal: No
Duration Type: Long-acting, Short-acting
Delivery Method: Oral
Developer: University of Washington, University of Minnesota
Development Stage: Pre-clinical
Alternative Name: ARC; triple hormone contraceptive; Triple OC
User: Female
Hormonal: Yes
Duration Type: Short-acting
Delivery Method: Oral
Developer: ANI Pharmaceuticals, Pantarhei Bioscience
Development Stage: Phase II
Alternative Name: Suspensories
User: Male
Hormonal: No
Duration Type: Short-acting
Delivery Method: Testicular
Developer: Centre Hospitalier Universitaire de Toulouse, France
Development Stage: Phase II
User: Female
Hormonal: Yes
Duration Type: Long-acting
Delivery Method: Subdermal
Developer: FHI 360, Yale University
Development Stage: Pre-clinical
User: Female
Hormonal: Yes
Duration Type: Long-acting
Delivery Method: Subdermal
Developer: Peking University, Institute of Biomedical Engineering at Chinese Academy of Medical College
Development Stage: Pre-clinical
User: Female
Hormonal: Yes
Duration Type: Long-acting
Delivery Method: Subdermal
Developer: Shanghai Institute of Planned Parenthood Research (SIPPR)
Development Stage: Pre-clinical
User: Female
Hormonal: Yes
Duration Type: Long-acting
Delivery Method: Subdermal
Developer: University of Washington
Development Stage: Pre-clinical
Alternative Name: BDADs
User: Female, Male
Hormonal: No
Duration Type: Short-acting
Delivery Method: Oral
Developer: Focused Scientific, University of Washington
Development Stage: Pre-clinical
User: Female
Hormonal: No
Duration Type: Short-acting
Delivery Method: Vaginal Gel
Developer: ReProtect Inc.
Development Stage: Phase III

Pages

Displaying 41 - 50 of 52
Alternative Name: MCR-165, Medicated Contraceptive Ring-165
User: Female
Hormonal: No
Duration Type: Long-acting
Delivery Method: Intrauterine
Developer: Shanghai Medical Suture Needle Factory
Development Stage: Marketed
Alternative Name: Depo-subQ + Uniject
User: Female
Hormonal: Yes
Duration Type: Short-acting
Delivery Method: Injectable
Developer: Pfizer, PATH, USAID
Development Stage: SRA/WHO PQ Approved
Alternative Name: Flomax
User: Male
Hormonal: No
Duration Type: Pericoital
Delivery Method: Oral
Development Stage: SRA/WHO PQ Approved
Alternative Name: IUD HBCu375/MCu375 and TCu380A
User: Female
Hormonal: No
Duration Type: Long-acting
Delivery Method: Intrauterine
Developer: Tianjin Medical Instrument Factory
Development Stage: Marketed
Alternative Name: Triclovera; OSKB -1
User: Female
Hormonal: Yes
Duration Type: Short-acting
Delivery Method: Injectable
Developer: PT. Tunggal Idaman Abdi
Development Stage: Marketed
Alternative Name: LNG Contraceptive IUS 12 (LCS12)
User: Female
Hormonal: Yes
Duration Type: Long-acting
Delivery Method: Intrauterine
Developer: Bayer HealthCare
Development Stage: Regulatory
User: Female
Hormonal: Yes
Duration Type: Long-acting
Delivery Method: Subdermal
Developer: Population Council, Theramex, Rockefeller Foundation
Development Stage: Marketed
User: Female
Hormonal: No
Duration Type: Pericoital
Delivery Method: Barrier
Developer: HLL Lifecare Limited
Development Stage: SRA/WHO PQ Approved
Alternative Name: Medicated Gamma IUD
User: Female
Hormonal: No
Duration Type: Long-acting
Delivery Method: Intrauterine
Development Stage: Marketed
Alternative Name: Medicated Gamma IUD
User: Female
Hormonal: No
Duration Type: Long-acting
Delivery Method: Intrauterine
Developer: Shanghai Medical Suture Needle Factory
Development Stage: Marketed

Pages

CSV